Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Questcor Pharmaceuticals rose 34 cents (1.1%) to $32.70 on average volume. Throughout the day, 1.9 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock ranged in a price between $31.70-$32.78 after having opened the day at $31.90 as compared to the previous trading day's close of $32.36. Other companies within the Drugs industry that increased today were: Nymox Pharmaceutical Corporation ( NYMX), up 25.6%, Atossa Genetics ( ATOS), up 24.5%, IGI ( IG), up 16.8%, and China Biologic Products ( CBPO), up 13.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $1.89 billion and is part of the health care sector. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 21.1% year to date as of the close of trading on Friday. Currently there are six analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and one rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Pernix Therapeutics Holdings ( PTX), down 12%, Idera Pharmaceuticals ( IDRA), down 10.8%, iBio ( IBIO), down 10%, and Supernus Pharmaceuticals ( SUPN), down 9.8%, were all laggards within the drugs industry with Merck ( MRK) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Cramer: Reviewing S&P's Hit-and-Miss Parade

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Greenberg on the Stock Market: Why Investigations No Longer Matter

Retrophin CEO Under Fire for Twitter Faux Pas

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today